Fetal Cells in Maternal Blood for Noninvasive Prenatal Testing—Is it Still a Distant Star?
Prenatal Diagnosis · 07.11.2026
DOI: 10.1002/pd.70304 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Prenatal Diagnosis, online erschienen am 07.11.2026. Verfasst von Ripudaman Singh und 14 weiteren Autor:innen. Beteiligte Einrichtung: ARCEDI Biotech, Vejle, Denmark. Die Arbeit nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: This work was funded by ARCEDI Biotech.
Abstract (Originalsprache)
Accurate and safe prenatal diagnosis of severe genetic disorders remains challenging despite advances in genomic technologies and increased use of cell‐free noninvasive prenatal testing (cfNIPT). Currently, approximately half of pathogenic copy number variants (pCNVs) and most monogenic disorders are identified only postnatally. cfNIPT primarily detects aneuploidies. Some extended cfNIPTs perform genome‐wide screening for larger pCNVs as well as selected microdeletion syndromes. Traditional invasive techniques, such as chorionic villus sampling (CVS), detect both aneuploidies and pCNVs but involve a slight risk of miscarriage. Emerging cell‐based noninvasive prenatal testing (cbNIPT) represents a promising advancement, potentially increasing prenatal detection rates by enabling accurate, safe, and comprehensive genome‐wide analysis, including small but clinically significant microdeletions, and monogenic disorders such as cystic fibrosis and sickle cell disease. In this review, we make a case for cbNIPT and describe its positioning with respect to cfNIPT. We also present the development of a cell‐based technology from finding fetal cell specific biomarkers, streamlining the technology of isolating cells from maternal blood, generating clinical data, and launching a test in the market. This advancement could substantially enhance informed decision‐making, timely clinical interventions, and pregnancy outcomes as compared to cfNIPT.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- ARCEDI Biotech, Vejle, Denmark.
- Department of Obstetrics and Gynaecology, Aarhus University Hospital, Aarhus N, Denmark.
- Department of Clinical Genetics, Aarhus N, Denmark.
- Center for Fetal Diagnostics, Aarhus University Hospital, Aarhus N, Denmark.
ORCID-Profile: Ripudaman Singh, Katarina Ravn, Line Dahl Jeppesen, Maria Bach Laursen, Maibritt Nøgaard Lauridsen, Marlene Christina Nielsen, Morten Muhlig Nielsen, Britt Kidmose Ardal, Lars Henning Pedersen, Ida Vogel, Lotte Hatt
Förderung
- This work was funded by ARCEDI Biotech
Zitieren
APA
Singh, R., Ravn, K., Jeppesen, L. D., Laursen, M. B., Lauridsen, M. N., Kølvraa, M., Nielsen, M. C., Nicolaisen, B. H., Cristensen, I. B., Nielsen, M. M., Ardal, B. K., Pedersen, L. H., Dalsgaard, M. T., Vogel, I., & Hatt, L. (2026). Fetal Cells in Maternal Blood for Noninvasive Prenatal Testing—Is it Still a Distant Star?. Prenatal Diagnosis. https://doi.org/10.1002/pd.70304
Vancouver
Singh R, Ravn K, Jeppesen LD, Laursen MB, Lauridsen MN, Kølvraa M, et al. Fetal Cells in Maternal Blood for Noninvasive Prenatal Testing—Is it Still a Distant Star?. Prenatal Diagnosis. 2026. doi:10.1002/pd.70304
BibTeX
@article{Singh2026,
author = {Singh, Ripudaman and Ravn, Katarina and Jeppesen, Line Dahl and Laursen, Maria Bach and Lauridsen, Maibritt Nøgaard and Kølvraa, Mathias and Nielsen, Marlene Christina and Nicolaisen, Bolette Hestbek and Cristensen, Inga Baach and Nielsen, Morten Muhlig and Ardal, Britt Kidmose and Pedersen, Lars Henning and Dalsgaard, Mads Tang and Vogel, Ida and Hatt, Lotte},
title = {Fetal Cells in Maternal Blood for Noninvasive Prenatal Testing—Is it Still a Distant Star?},
journal = {Prenatal Diagnosis},
year = {2026},
doi = {10.1002/pd.70304}
}
EUVIMED